USANA Health Sciences Inc (USNA)
Cash ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 330,420 | 288,420 | 239,832 | 311,917 | 234,830 |
| Short-term investments | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 118,845 | 143,833 | 160,790 | 168,073 | 136,098 |
| Cash ratio | 2.78 | 2.01 | 1.49 | 1.86 | 1.73 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($330,420K
+ $—K)
÷ $118,845K
= 2.78
The cash ratio of USANA Health Sciences Inc has shown an increasing trend over the past five years, indicating the company's improving ability to cover its short-term liabilities with its available cash and cash equivalents. As of December 31, 2023, the cash ratio stands at 2.78, which means the company holds $2.78 in cash and cash equivalents for every $1 of current liabilities. This suggests a strong liquidity position for USANA Health Sciences Inc, providing a buffer to meet its immediate financial obligations. The consistent improvement in the cash ratio reflects prudent cash management and a stable financial position for the company.